Pediatric Cancer Clinical Trial
Official title:
CanMove: The Feasibility of Implementing a Physical Activity Intervention for Children Undergoing Acute Cancer Treatment
Verified date | June 2022 |
Source | Murdoch Childrens Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate a physical activity intervention for children during acute cancer treatment. The intervention aims to encourage children to participate in increased levels of physical activity and reduce the amount of time they spend engaged in sedentary activities. This study also aims to evaluate different ways of assessing physical function in order to determine the best outcome measure to use for children during acute cancer treatment.
Status | Completed |
Enrollment | 21 |
Est. completion date | September 3, 2021 |
Est. primary completion date | September 3, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 17 Years |
Eligibility | Inclusion Criteria: - Is between the ages of 5-17 years at the time of consent - Diagnosed (or relapsed) with cancer >4 weeks and <6 months at time of consent - Currently receiving cancer treatment at the Royal Children's Hospital - Has been an in-patient for >7 consecutive days at the time of consent - Provide a signed and dated informed consent form and/or has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf Exclusion Criteria: - Deemed by the treating medical team as unsafe to participate - Child/adolescent unable to mobilise independent of clinical staff assistance, as classified by the research team at the time of consent (use of a gait aid or assistance from a primary carer/support person is accepted). For example, if a child/adolescent requires assistance from nursing staff or physiotherapist in order to walk, they will be excluded. - Child/adolescent unable to follow simple instructions - Suitable support person (18 years and over) not available to participate in continuous monitoring of daily steps in tandem with the child/adolescent - No suitable access to a device to sync with a Fitbit - Inability or unwillingness of participant or legally acceptable representative to give written informed consent. |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Children's Hospital | Parkville | Victora |
Lead Sponsor | Collaborator |
---|---|
Murdoch Childrens Research Institute | La Trobe University |
Australia,
Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, Bakken S, Kaplan CP, Squiers L, Fabrizio C, Fernandez M. How we design feasibility studies. Am J Prev Med. 2009 May;36(5):452-7. doi: 10.1016/j.amepre.2009.02.002. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Construct validity of physical function measures | Correlation between scores of all physical function measures: Timed up and Go, Movement ABC, Timed Up and Down Stairs, 6 Minute Walk Test, Time to Rise from the Floor | Post completion of follow up assessment (on average 10 weeks) | |
Other | Interpretability of physical function measures | Interpretability assessment of all physical function measures used in the trial: Timed up and Go, Movement ABC, Timed Up and Down Stairs, 6 Minute Walk Test, Time to Rise from the Floor | Post completion of follow up assessment (on average 10 weeks) | |
Other | Responsiveness of physical function measures | Correlation in mean change over two time points between all physical function measures used in the trial: Timed up and Go, Movement ABC, Timed Up and Down Stairs, 6 Minute Walk Test, Time to Rise from the Floor and Global Rating of Change Score | Post completion of follow up assessment (on average 10 weeks) | |
Other | Criterion validity of physical activity measured on the Fitbit and Actigraph | Correlation of physical activity data between Fitbit and Actigraph | Post completion of follow up assessment (on average 10 weeks) | |
Primary | Demand for the intervention | Recruitment rate (comparing the number of people recruited to the number of potentially eligible participants), and documenting the reasons for non-participation. | Through completion of recruitment, estimated as 9 months | |
Primary | Acceptability of the intervention according to participants | Participant and participant guardian perspective on intervention satisfaction and potential areas of improvement via semi-structured interviews | After completion of the intervention (on average 8 weeks) | |
Primary | Acceptability of the intervention according to staff | Staff perspective on intervention satisfaction and potential areas of improvement via focus groups with staff members | Through study completion, estimated as 1 year | |
Primary | Implementation of the intervention: adherence to wearing Fitbit | Adherence to wearing the Fitbit for monitoring, percentage of complete Fitbit data days out of total intervention days | Post intervention (on average 8 weeks) | |
Primary | Implementation of the intervention: attendance to intervention sessions | Adherence to attending intervention sessions, percentage of intervention sessions that were attended | Post intervention (on average 8 weeks) | |
Primary | Implementation of the intervention: ability for participants to attain their steps per day goal | Goal attainment, percentage of days out of total intervention days that participant was able to achieve their steps per day target | Post intervention (on average 8 weeks) | |
Primary | Practicality of the intervention: adverse events | Measured by number of adverse events reported related to trial procedures. At each trial visit, participants will be asked "How have you felt since your last visit?" in order to elicit any changes in their well-being. They will also be asked if they have had any falls, new injuries, felt distress as a result of the intervention or experienced a change in medical or mobility status. Adverse events relevant to participant safety will also be documented from correspondence from their primary care physician or from the medical record. Adverse events recorded as serious or non-serious, related or not related to the intervention. | Post the participant's final trial visit (on average 12 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: Actigraph steps per day | Mean change from pre to post intervention in average steps taken per day measured via the Actigraph | Post intervention (on average 8 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: Fitbit steps per day | Mean change from pre to post intervention in average steps taken per day measured via the Fitbit | Post intervention (on average 8 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: Actigraph distance travelled per day | Mean change from pre to post intervention in average distance travelled per day measured via the Actigraph | Post intervention (on average 8 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: Fitbit distance travelled per day | Mean change from pre to post intervention in average distance travelled per day measured via the Fitbit | Post intervention (on average 8 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: Actigraph physical activity intensity | Mean change from pre to post intervention in time spent in different physical activity intensities (sedentary, light, moderate-vigorous and vigorous) measured by the Actigraph | Post intervention (on average 8 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: Fitbit physical activity intensity | Mean change from pre to post intervention in time spent in different physical activity intensities (sedentary, light, moderate-vigorous and vigorous) measured by the Fitbit | Post intervention (on average 8 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: sedentary bouts | Mean change from pre to post intervention in number of sedentary bouts per day measured via the Actigraph | Post intervention (on average 8 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: body position | Mean change from pre to post intervention in time spent in each body position per day measured via the Actigraph | Post intervention (on average 8 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: active hours | Mean change from pre to post intervention in number of active hours per day measured via the Fitbit | Post intervention (on average 8 weeks) | |
Primary | Limited efficiency testing assessing changes in physical activity between pre and post intervention: active minutes | Mean change from pre to post intervention in number of active minutes per day measured via the Fitbit | Post intervention (on average 8 weeks) | |
Secondary | Limited efficiency testing assessing changes in physical function from pre to post intervention: Movement ABC | Mean score and percentile ranking measured via on the Movement ABC (a performance measure of physical function) | Post intervention (on average 8 weeks) | |
Secondary | Limited efficiency testing assessing changes in physical function from pre to post intervention: 6 Minute Walk Test | Mean distance travelled measured via on the 6 Minute Walk test (a performance measure of physical fitness) | Post intervention (on average 8 weeks) | |
Secondary | Limited efficiency testing assessing changes in physical function from pre to post intervention: Timed Up and Go | Mean time measured via the Timed Up and Go (a performance measure of physical function) | Post intervention (on average 8 weeks) | |
Secondary | Limited efficiency testing assessing changes in physical function from pre to post intervention: Timed Up and Down Stairs | Mean time measured via the Timed Up and Down Stairs (a performance measure of physical function) | Post intervention (on average 8 weeks) | |
Secondary | Limited efficiency testing assessing changes in physical function from pre to post intervention: Time to Rise from the Floor | Mean time and rating for quality of movement measured via the 30 second Chair Stand Test Assessment (a performance measure of physical function) | Post intervention (on average 8 weeks) | |
Secondary | Limited efficiency testing assessing changes in physical function from pre to post intervention: Time to Rise from the Floor | Mean time and rating for quality of movement measured via the Time to Rise from the Floor Assessment (a performance measure of physical function) | Post intervention (on average 8 weeks) | |
Secondary | Limited efficiency testing assessing changes in Health-related Quality of Life from pre to post intervention: self-reported Pediatric Quality of Life Inventory-core generic module | Mean score recorded on the self-reported Pediatric Quality of Life Inventory-core generic module (standardised questionnaire). Items are scored on a 0-100 scale, so that higher scores indicate better health-related quality of life | Post intervention (on average 8 weeks) | |
Secondary | Limited efficiency testing assessing changes in Health-related Quality of Life from pre to post intervention: proxy-reported Pediatric Quality of Life Inventory-core generic module | Mean score recorded on the proxy-reported Pediatric Quality of Life Inventory-core generic module (standardised questionnaire). Items are scored on a 0-100 scale, so that higher scores indicate better health-related quality of life | Post intervention (on average 8 weeks) | |
Secondary | Feasibility: Limited efficiency testing assessing changes in Health-related Quality of Life from pre to post intervention: self-reported PedsQL-cancer module | Mean score recorded on the self-reported Pediatric Quality of Life Inventory-cancer module (standardised questionnaire). Items are scored on a 0-100 scale, so that higher scores indicate better health-related quality of life | Post intervention (on average 8 weeks) | |
Secondary | Feasibility: Limited efficiency testing assessing changes in Health-related Quality of Life from pre to post intervention: proxy-reported PedsQL-cancer module | Mean score recorded on the proxy-reported Pediatric Quality of Life Inventory-cancer module (standardised questionnaire). Items are scored on a 0-100 scale, so that higher scores indicate better health-related quality of life | Post intervention (on average 8 weeks) | |
Secondary | Categorisation and frequency of reported barriers to physical activity | Categorise and collate the frequency of participant reported barriers to physical activity. Data collected during each week of the intervention period | Post intervention (on average 8 weeks) | |
Secondary | Categorisation and frequency of action plan strategies | Categorise and collate the frequency of action plan items put in place to overcome barriers to physical activity. Data collected during each week of the intervention period | Post intervention (on average 8 weeks) | |
Secondary | Utility of physical function assessment tools, measured by completeness of assessment data for physical function | The percentage of physical function assessments that were completed | Post completion of follow up assessment (on average 10 weeks) | |
Secondary | Utility of physical activity assessment tools, measured by completeness of assessment data for physical activity | Percentage of complete Fitbit and Actigraph data days out of total assessment days | Post completion of follow up assessment (on average 10 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Not yet recruiting |
NCT06335745 -
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
|
N/A | |
Withdrawn |
NCT04719416 -
Relaxation Therapy in Pediatric Oncology
|
N/A | |
Completed |
NCT01645436 -
Physical Activity in Pediatric Cancer (PAPEC)
|
N/A | |
Completed |
NCT04409301 -
Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation
|
N/A | |
Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
Recruiting |
NCT05425043 -
Granulocyte Transfusions After Umbilical Cord Blood Transplant
|
N/A | |
Recruiting |
NCT05071859 -
Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
|
||
Recruiting |
NCT03241251 -
Screening for Psychosocial Risk in Flemish Families of a Child With Cancer
|
||
Recruiting |
NCT05384288 -
Response to Influenza Vaccination in Pediatric Oncology Patients
|
||
Completed |
NCT04586491 -
The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients
|
N/A | |
Recruiting |
NCT05569512 -
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05294380 -
Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
|
||
Completed |
NCT02665819 -
Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility.
|
N/A | |
Completed |
NCT02675166 -
Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes
|
||
Not yet recruiting |
NCT05454163 -
Post-radiotherapy Rhinosinusitis in Children
|
||
Terminated |
NCT02536183 -
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01828502 -
Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer
|
Phase 2 | |
Completed |
NCT02032121 -
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
|
N/A | |
Completed |
NCT03964259 -
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
|
Phase 1 |